<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352506</url>
  </required_header>
  <id_info>
    <org_study_id>1680/2014</org_study_id>
    <nct_id>NCT02352506</nct_id>
  </id_info>
  <brief_title>Serum MIF in Acute Kidney Injury</brief_title>
  <official_title>Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) is a common complication in critical care patients. Currently no&#xD;
      parameters are available for early prognosis of AKI. Macrophage migration inhibitory factor&#xD;
      (MIF) has been associated with AKI in clinical studies. The aim of this study is to evaluate&#xD;
      the time course of MIF concentrations in patients with AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Macrophage migration inhibitory factor</measure>
    <time_frame>Up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>AKI</arm_group_label>
    <description>Patients developing AKI during the ICU stay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No AKI</arm_group_label>
    <description>Matched controls not developing AKI during the ICU stay</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw for measurement of MIF</intervention_name>
    <description>Observational study, no intervention</description>
    <arm_group_label>AKI</arm_group_label>
    <arm_group_label>No AKI</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Critical care patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years and &gt; 80 years&#xD;
&#xD;
          -  Patients with chronic dialysis&#xD;
&#xD;
          -  Patients with continuous hemodialysis, hemofiltration or hemodiafiltration within 4&#xD;
             weeks prior to the study&#xD;
&#xD;
          -  Patients with an expected length of ICU stay shorter than 3 days&#xD;
&#xD;
          -  Patients with a low probability of surviving the first 2 days after ICU admission&#xD;
&#xD;
          -  Pregnancy and nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>January 1, 2021</last_update_submitted>
  <last_update_submitted_qc>January 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>David M Baron, MD</investigator_full_name>
    <investigator_title>Univ.-Ass.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

